By Editor , 13 September 2026 Evotec Biologics Moves U.S. War Dept. Antibody JST-018 to Phase 1 Seattle – September 12, 2026 -- Just – Evotec Biologics has initiated a first-in-human Phase 1 clinical trial for JST-018, a monoclonal antibody cocktail targeting orthopoxviruses, developed under a U.S. Department of War contract.
